Brain atrophy and white matter hyperintensities in early Parkinson's disease

Movement Disorders

Volumn 24, Issue 15, 2009, Pages 2233-2241

  Dalaker, Turi O ^a,b   Larsen, Jan P ^b,c   Bergsland, Niels ^a   Beyer, Mona K ^b   Alves, Guido ^b   Dwyer, Michael G ^a   Tysnes, Ole Bjorn ^c,d   Benedict, Ralph H B ^a,e   Kelemen, Arpad ^a   Bronnick, Kolbjorn ^b   Zivadinov, Robert ^a,e,f  

^a UNIVERSITY AT BUFFALO   (United States)

^b STAVANGER UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e JACOBS NEUROLOGICAL INSTITUTE   (United States)

^f STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Brain atrophy; Cognition; MRI; Parkinson's disease; SIENAX; White matter hyperintensities

Indexed keywords

AGE DISTRIBUTION; AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CALCULATION; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; WHITE MATTER;

AGED; ATROPHY; BRAIN; CASE-CONTROL STUDIES; COHORT STUDIES; EXECUTIVE FUNCTION; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MEMORY; MENTAL STATUS SCHEDULE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NERVE FIBERS, MYELINATED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC;

EID: 72849153679     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22754     Document Type: Article

References (44)

1. Braak H, Bohl JR, Muller CM, Rub U, De Vos RA, Del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006;21:2042-2051.
2. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004;127:550-560.
3. Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996;53:538-542.
4. Mayeux R, Denaro J, Hemenegildo N. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 1992;49:492-497.
5. Zivadinov R, Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging 2004;14 (Suppl):27S-35S. (Pubitemid 38781409)
6. Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol 2000;57:339-344. (Pubitemid 30140520)
7. Beyer MK, Janvin CC, Larsen JP, Aarsland D. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007;78:254-259. (Pubitemid 46579662)
8. Burton EJ, Mckeith IG, Burn DJ, Williams ED, O'brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004;127:791-800.
9. Junque C, Ramirez-Ruiz B, Tolosa E. Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia. Mov Disord 2005;20:540-544. (Pubitemid 40862250)
10. Nagano-Saito A, Washimi Y, Arahata Y. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005;64:224-229.
11. Geng DY, Li YX, Zee CS. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease. Neurosurgery 2006;58:256- 262; discussion.
12. Almeida OP, Burton EJ, Mckeith I, Gholkar A, Burn D, O'brien JT. MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease. Dement Geriatr Cognit Disord 2003;16:57-63.
13. De Leeuw FE, De Groot JC, Achten E. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001;70:9-14.
14. Liao D, Cooper L, Cai J. The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC Study. Neuroepidemiology 1997;16:149-162. (Pubitemid 27215864)
15. Van Der Flier WM, Van Straaten EC, Barkhof F. Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke 2005;36:2116-2120. (Pubitemid 41429230)
16. Beyer MK, Aarsland D, Greve OJ, Larsen JP. Visual rating of white matter hyperintensities in Parkinson's disease. Mov Disord 2006;21:223-229.
17. Burton EJ, Mckeith IG, Burn DJ, Firbank MJ, O'brien JT. Progression of white matter hyperintensities in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia: a comparison with normal aging. Am J Geriatr Psychiatry 2006; 14:842-849.
18. Alves G, Muller B, Herlofson K. Incidence of Parkinson's disease in Norway. The Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2009;80:851-857.
19. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
20. Fahn S, Elton R, Marsdan C, Al E. Unified Parkinson's disease rating scale. In: Recent developments in Parkinson's disease. Fahn S, Marsden CD, Calnse DM, et al., eds. Florham Park, NJ: McMillian Healthcare Information 1987; p 153-163.
21. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
22. Folstein MF, Folstein SE, Mchugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389. (Pubitemid 9136500)
24. Woods SP, Delis DC, Scott JC, Kramer JH, Holdnack JA. The California verbal learning test, second edition. Test-retest reliability, practice effects, and reliable change indices for the standard and alternate forms. Arch Clin Neuropsychol 2006;21:413-420.
25. Warrington EK, James M. A new test of object decision: 2D silhouettes featuring a minimal view. Cortex 1991;27:370-383.
26. Golden CJ. Identification of brain disorders by the Stroop Color and Word Test. J Clin Psychol 1976;32:654-658.
27. Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2008;72:1121-1126.
28. Smith SM, Zhang Y, Jenkinson M. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002;17:479-489.
29. Zivadinov R, Rudick RA, De Masi R. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-1247. (Pubitemid 32947383)
30. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community- based study. Ann Neurol 2005;58:773-776. (Pubitemid 41552553)
31. Jellinger KA. The morphological basis of mental dysfunction in Parkinson's disease. J Neurol Sci 2006;248:167-172. (Pubitemid 44647294)
32. Emre M. What causes mental dysfunction in Parkinson's disease?. Mov Disord 2003;18(Suppl 6):S63-S71. (Pubitemid 37185198)
33. Hilker R, Thomas AV, Klein JC. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65:1716-1722. (Pubitemid 43754399)
34. Ashburner J, Friston KJ. Voxel-based morphometry - the methods. Neuroimage 2000;11(6 Part 1):805-821.
35. Laakso MP, Partanen K, Riekkinen P. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996;46:678-681. (Pubitemid 26099632)
36. Tessa C, Giannelli M, Nave RD. A whole-brain analysis in de novo Parkinson disease. AJNR Am J Neuroradiol 2008;29: 674-680. (Pubitemid 351571545)
37. Braak H, Del Tredici K, Rub U, De Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211. (Pubitemid 36007810)
38. Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 2007;6:926-932. (Pubitemid 47405003)
39. Burns JM, Church JA, Johnson DK. White matter lesions are prevalent but differentially related with cognition in aging and early Alzheimer disease. Arch Neurol 2005;62:1870-1876.
40. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F. Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 2006;37:1184-1188. (Pubitemid 43731859)
41. Allcock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a community based cohort of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75:1470-1471. (Pubitemid 39279820)
42. Ballard C, O'brien J, Barber B. Neurocardiovascular instability, hypotensive episodes, and MRI lesions in neurodegenerative dementia. Ann N Y Acad Sci 2000;903:442-445.
43. Levy G. The relationship of Parkinson disease with aging. Arch Neurol 2007;64:1242-1246.
44. Van Straaten EC, Fazekas F, Rostrup E. Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke 2006;37:836-840. (Pubitemid 43731918)